A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2002
11/14/2002	WO2002089794A1 Method for treating neuropathic pain and pharmaceutical preparation therefor
11/14/2002	WO2002089793A1 Sulfonamides
11/14/2002	WO2002089792A1 Sulfonamides
11/14/2002	WO2002089791A2 Acne treatment with lipooxigenase inhibitors
11/14/2002	WO2002089790A1 Treatment of hpv caused diseases
11/14/2002	WO2002089789A1 Trimethyl lock based tetrapartate prodrugs
11/14/2002	WO2002089788A2 Pharmaceutical compositions comprising a hmg-coa reductase inhibitor
11/14/2002	WO2002089787A1 Potentiation of therapeutic effects of fatty acids
11/14/2002	WO2002089786A1 Compositions for improving mental concentration
11/14/2002	WO2002089785A1 Sulfonamides
11/14/2002	WO2002089784A1 Novel sphingolipid synthesis inhibitor
11/14/2002	WO2002089783A1 Substituted cyclohexan-1,4-diamine derivatives with constipating and peripheral analgesic properties
11/14/2002	WO2002089781A2 Methods of treating hyperlipidemia
11/14/2002	WO2002089780A2 Antiviral compounds
11/14/2002	WO2002089779A2 Combined preparation for the prophylaxis and/or therapy of nerve cell and/or glia cell damage using a novel method of treatment
11/14/2002	WO2002089778A2 Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
11/14/2002	WO2002089777A1 Improved transdermal therapeutic system for the treatment of parkinson's disese
11/14/2002	WO2002089776A1 Nanoparticles made of protein with coupled apolipoprotein e for penetration of the blood-brain barrier and methods for the production thereof
11/14/2002	WO2002089775A1 Coated granules based on angiotensin-converting enzyme inhibitor
11/14/2002	WO2002089770A2 Topical lamellar double membrane structure composition containing n-acyl-ethanolamine and/or a quaternary ammonium salt and/or adenosylmethionine
11/14/2002	WO2002089768A1 Liquid injectable formulation of disodium pamidronate
11/14/2002	WO2002089758A1 Use of oligomeric proanthrocyanidins
11/14/2002	WO2002089757A2 Use of isoflavones in cosmetic or dermatological preparations
11/14/2002	WO2002089755A1 Cationic antibacterial dentifrice exhibiting superior foaming properties
11/14/2002	WO2002089751A1 System and method for intranasal administration of lorazepam
11/14/2002	WO2002089749A2 Arylsulfonamide ethers, and methods of use thereof
11/14/2002	WO2002089747A2 Compositions and methods for the therapy and diagnosis of prostate cancer
11/14/2002	WO2002089745A2 Substituted n'-(arylcarbonyl)-benzhydrazides, n'-(arylcarbonyl)-benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof
11/14/2002	WO2002089743A2 Use of compositions for treating rosacea
11/14/2002	WO2002089741A2 Compositions and methods for enhancing drug delivery
11/14/2002	WO2002089740A2 Sulfonamides
11/14/2002	WO2002089736A2 Adenosine a1 receptor antagonists for treating hypoxia-induced learning and memory impairment
11/14/2002	WO2002089734A2 Method for treatment and prevention of disturbances of the central nervous system associated with an alteration of glutamatergic neurotransmission by administration of 2-aminobenzenesulfonamide derivatives
11/14/2002	WO2002089730A2 Compounds and methods for the modulation of cd154
11/14/2002	WO2002089729A2 Fused heterocyclic compounds
11/14/2002	WO2002089584A1 Ectoparasiticidal compositions and methods of their use
11/14/2002	WO2002089581A1 Antimicrobial compounds and methods for their use
11/14/2002	WO2002081453A8 Thiohydantoins and use thereof for treating diabetes
11/14/2002	WO2002076990A8 Thiazolopyrimidine derivatives and use thereof as antagonists of the cx3 cr1 receptor
11/14/2002	WO2002076476A3 Prodrugs of anticancer agents employing substituted aromatic acids
11/14/2002	WO2002074764A3 Piperazine derivatives and their use as 5-ht1b ligands
11/14/2002	WO2002072577A3 Azacycloalkyl substituted acetic acid derivatives for use as mmp inhibitors.
11/14/2002	WO2002072089A3 Use of thiolutin dioxide and its derivatives in the manufacture of a medicament for the treatment of cns disorders and a process for the preparation thereof
11/14/2002	WO2002069963A3 Compositions comprising ferulic acid, caffeic acid, tannic acid or ellagic acid and their use for the preparation of a medicament for the treatment of dermatological disorders
11/14/2002	WO2002068417A3 Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
11/14/2002	WO2002067913A8 (z)-styrylbenzylsulfones and pharmaceutical uses thereof
11/14/2002	WO2002067831B1 Composition for freshening nostrils and sinus cavities
11/14/2002	WO2002066028A3 Pharmaceutical compositions containing fluorinated or perfluorinated carboxylic acids
11/14/2002	WO2002064616A3 Agonists and antagonists of sphingosine-1-phosphate receptors
11/14/2002	WO2002064550A8 Glucocorticoid receptor modulators
11/14/2002	WO2002062392A3 Water-soluble compositions of bioactive lipophilic compounds
11/14/2002	WO2002062324A3 A treatment of oesophageal motility disorders and gastro-oesophageal reflux disease
11/14/2002	WO2002060339A3 Ophthalmic compositions for treating ocular hypertension
11/14/2002	WO2002057239A3 Pyrimidine phosphorylase as a target for imaging and therapy
11/14/2002	WO2002056876A3 Treatment for snoring
11/14/2002	WO2002055014A3 Therapeutic chroman compounds
11/14/2002	WO2002055013A3 Therapeutic chromone compounds
11/14/2002	WO2002055012A3 Therapeutic heterocyclic compounds
11/14/2002	WO2002051419A3 A pharmaceutical composition containing benzopyrano-oxopyrimidotetrahydrothiazine and its use in the treatment of hiv
11/14/2002	WO2002049634A3 Dissociated glucocorticoid receptor antagonists for the treatment of clucocorticoid associated side-effect
11/14/2002	WO2002045688A3 Composition for treatment of inflammatory disorders
11/14/2002	WO2002038534A3 Substituted alkyldiamines as inhibitors of plasmepsin or related proteases
11/14/2002	WO2002034073A3 Compositions containing flavonoids and phlorizin or phloretin
11/14/2002	WO2002030385A3 Anti-inflammatory active ingredients
11/14/2002	WO2002028906A3 Regulation of human sphingosine kinase-like protein
11/14/2002	WO2002024650B1 Pyridinone and pyridinethione derivatives having hiv inhibiting properties
11/14/2002	WO2002018404A3 Nucleoside derivatives for the treatment of hepatitis c
11/14/2002	WO2002010151A3 Method for producing lipoic acid and dihydrolipoic acid
11/14/2002	WO2002007782A3 Diagnosis of liver disease
11/14/2002	WO2002007718A8 Method for the treatment of climacteric disorders in women during or after the menopause
11/14/2002	WO2002007713A3 Medicaments containing cilansetron for treating non-obstipated male ibs patients
11/14/2002	WO2001097787A3 Use of microsomal triglyceride transfer protein (mtp) inhibitors for reducing the number of postprandial triglyceride-rich lipoprotein particles (pptrl)
11/14/2002	WO2001062235A3 A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
11/14/2002	WO2001035106A3 Methods for identifying and using amyloid-inhibitory compounds
11/14/2002	WO2001024831A9 Polymer stabilized neuropeptides
11/14/2002	WO2001007030A3 Compositions an inhibitor of an accrab-like efflux pump for reducung microbial resistance to drugs
11/14/2002	US20020169439 Modular infusion device and method
11/14/2002	US20020169341 Form A of fluoxetine hydrochloride in pure form characterized by having an x-ray powder diffraction pattern consistent with fluoxetine hydrochloride, having a single endotherm as determined by differential scanning calorimetry
11/14/2002	US20020169336 Able to inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders
11/14/2002	US20020169332 Linoleic acid is converted to its conjugated forms in which the resulting composition is low in certain unusual isomers compared to conventional conjugated linoleic products
11/14/2002	US20020169328 Mitomycin C and pyrrolo(1,2-a)benzimidazole; exposing microorganisms to first agent which induces expression of protein which inactivates mitomycin c then to second agent which is activated by same protein which inactivates first
11/14/2002	US20020169326 Fatty acid derivatives
11/14/2002	US20020169325 Useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia, atherosclerosis, gastrointestinal disorders
11/14/2002	US20020169322 Use of N-alkylamino-heterocylic compounds for the treatment of migraine
11/14/2002	US20020169320 Tetrahydropyridoethers
11/14/2002	US20020169318 Novel thrombin inhibitors
11/14/2002	US20020169317 Oxazinocarbazoles for the treatment of CNS diseases
11/14/2002	US20020169314 Sulfonamide derivative as a matrix metalloproteinase inhibitor
11/14/2002	US20020169301 Nucleotide sequences coding polypeptide for use in the diagnosis and treatment of cell proliferative disorders
11/14/2002	US20020169287 Nucleotide sequences coding polypeptide for use in the treatment of eating, dieteticad energy disorders
11/14/2002	US20020169284 Nucleotide sequences coding polypeptide for use in the treatment of tumors, nervous system, virus, and visoin disorders
11/14/2002	US20020169215 Treatment of a disease that is mediated by the expression or suppression of a redox sensitive gene, for example MCP-1, IL-6 and thrombin receptor; antiinflammatory agents; cardio-vascular disorders; atherosclerosis; immunology
11/14/2002	US20020169214 Methods and compositions for inactivating viruses
11/14/2002	US20020169213 Outstanding agonistic effect on alpha-1L-receptors; highly selective on the contractile mechanisms of the bladder without affecting other organs e.g., peripheral blood vessels; particularly incontinence due to stress
11/14/2002	US20020169212 A readily water-soluble ingestible form of ketoprofen formed by the reaction with any edible weak base to yield a palatable, stable, safe solution and including an sweetener for flavor; feeds; veterinary medicine
11/14/2002	US20020169211 Magnesium di-potassium EDTA complex and method of administration
11/14/2002	US20020169210 Method for treating or preventing bone fracture
11/14/2002	US20020169209 Potentiation of therapeutic effects of fatty acids
11/14/2002	US20020169208 Oxybutynin analogs; antichloinergic agents; side effect reduction; short half-life; water-soluble metabolites; incontinence; mydriatic and bronchodilator agents; respiratory system disorders; antiperspirants
11/14/2002	US20020169207 Inhibiting collagen-induced platelet aggregation

1 ... 5649 5650 5651 5652 5653 5654 5655 5656 5657 5658 5659 5660 5661 5662 5663 5664 5665 5666 5667 5668 5669 ... 7860